Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK- ALCL.

Andersson EI, Brück O, Braun T, Mannisto S, Saikko L, Lagström S, Ellonen P, Leppä S, Herling M, Kovanen PE, Mustjoki S.

Cancers (Basel). 2020 Mar 16;12(3). pii: E702. doi: 10.3390/cancers12030702.

2.

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Pützer S, Varghese L, von Jan J, Braun T, Giri AK, Mayer P, Riet N, Timonen S, Oberbeck S, Kuusanmäki H, Mustjoki S, Stern MH, Aittokallio T, Newrzela S, Schrader A, Herling M.

Leukemia. 2020 Feb 25. doi: 10.1038/s41375-020-0772-6. [Epub ahead of print] No abstract available.

PMID:
32099034
3.

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.

Autio M, Leivonen SK, Brück O, Mustjoki S, Jørgensen JM, Karjalainen-Lindsberg ML, Beiske K, Holte H, Pellinen T, Leppä S.

Haematologica. 2020 Feb 20. pii: haematol.2019.243626. doi: 10.3324/haematol.2019.243626. [Epub ahead of print]

4.

Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency.

Tuovinen EA, Grönholm J, Öhman T, Pöysti S, Toivonen R, Kreutzman A, Heiskanen K, Trotta L, Toiviainen-Salo S, Routes JM, Verbsky J, Mustjoki S, Saarela J, Kere J, Varjosalo M, Hänninen A, Seppänen MRJ.

J Clin Immunol. 2020 Feb 19. doi: 10.1007/s10875-020-00745-2. [Epub ahead of print]

PMID:
32072341
5.

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.

Söderlund S, Persson I, Ilander M, Guilhot J, Hjorth-Hansen H, Koskenvesa P, Richter J, Saussele S, Mustjoki S, Olsson-Strömberg U.

Leuk Res. 2020 Mar;90:106310. doi: 10.1016/j.leukres.2020.106310. Epub 2020 Jan 23.

PMID:
32058176
6.

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.

Adnan Awad S, Kankainen M, Ojala T, Koskenvesa P, Eldfors S, Ghimire B, Kumar A, Kytölä S, Kamel MM, Heckman CA, Porkka K, Mustjoki S.

Blood Adv. 2020 Feb 11;4(3):546-559. doi: 10.1182/bloodadvances.2019000943.

7.

Model-based inference and classification of immunological control mechanisms from TKI cessation and dose reduction in CML patients.

Hähnel T, Baldow C, Guilhot J, Guilhot F, Saussele S, Mustjoki S, Jilg S, Jost PJ, Dulucq S, Mahon FX, Roeder I, Fassoni AC, Glauche I.

Cancer Res. 2020 Feb 10. pii: canres.2175.2019. doi: 10.1158/0008-5472.CAN-19-2175. [Epub ahead of print]

PMID:
32041835
8.

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.

Kasanen H, Hernberg M, Mäkelä S, Brück O, Juteau S, Kohtamäki L, Ilander M, Mustjoki S, Kreutzman A.

Cancer Immunol Immunother. 2020 Feb 8. doi: 10.1007/s00262-020-02497-9. [Epub ahead of print]

PMID:
32036449
9.

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.

Brück O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, Kovanen P, Pallaud C, Ramos PM, Lähteenmäki H, Välimäki K, El Missiry M, Ribeiro A, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S.

Blood Adv. 2020 Jan 28;4(2):274-286. doi: 10.1182/bloodadvances.2019000792.

10.

Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies.

Halkola AS, Parvinen K, Kasanen H, Mustjoki S, Aittokallio T.

J Theor Biol. 2020 Mar 7;488:110136. doi: 10.1016/j.jtbi.2019.110136. Epub 2019 Dec 27.

11.

Novel TMEM173 Mutation and the Role of Disease Modifying Alleles.

Keskitalo S, Haapaniemi E, Einarsdottir E, Rajamäki K, Heikkilä H, Ilander M, Pöyhönen M, Morgunova E, Hokynar K, Lagström S, Kivirikko S, Mustjoki S, Eklund K, Saarela J, Kere J, Seppänen MRJ, Ranki A, Hannula-Jouppi K, Varjosalo M.

Front Immunol. 2019 Dec 5;10:2770. doi: 10.3389/fimmu.2019.02770. eCollection 2019.

12.

Somatic mutations and T-cell clonality in patients with immunodeficiency.

Savola P, Martelius T, Kankainen M, Huuhtanen J, Lundgren S, Koski Y, Eldfors S, Kelkka T, Keränen MAI, Ellonen P, Kovanen PE, Kytölä S, Saarela J, Lähdesmäki H, Seppänen MRJ, Mustjoki S.

Haematologica. 2019 Dec 19. pii: haematol.2019.220889. doi: 10.3324/haematol.2019.220889. [Epub ahead of print]

13.

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.

Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, Pölönen P, Hohtari H, Saeed K, Hannunen T, Ellonen P, Steinberger P, Kankainen M, Aittokallio T, Keränen MAI, Korhonen M, Mustjoki S.

Blood. 2020 Feb 27;135(9):597-609. doi: 10.1182/blood.2019002121.

PMID:
31830245
14.

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.

Wahnschaffe L, Braun T, Timonen S, Giri AK, Schrader A, Wagle P, Almusa H, Johansson P, Bellanger D, López C, Haferlach C, Stern MH, Dürig J, Siebert R, Mustjoki S, Aittokallio T, Herling M.

Cancers (Basel). 2019 Nov 21;11(12). pii: E1833. doi: 10.3390/cancers11121833.

15.

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types.

Majumder MM, Leppä AM, Hellesøy M, Dowling P, Malyutina A, Kopperud R, Bazou D, Andersson E, Parsons A, Tang J, Kallioniemi O, Mustjoki S, O'Gorman P, Wennerberg K, Porkka K, Gjertsen BT, Heckman CA.

Haematologica. 2019 Aug 22. pii: haematol.2019.217414. doi: 10.3324/haematol.2019.217414. [Epub ahead of print]

16.

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.

Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, Kasanen T, Koskenvesa P, Lotfi K, Markevärn B, Olsson-Strömberg U, Stentoft J, Stenke L, Söderlund S, Udby L, Richter J, Hjorth-Hansen H, Mustjoki S.

Oncoimmunology. 2019 Jul 13;8(9):e1638210. doi: 10.1080/2162402X.2019.1638210. eCollection 2019.

17.

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA.

Haematologica. 2020 Mar;105(3):708-720. doi: 10.3324/haematol.2018.214882. Epub 2019 Jul 11. No abstract available.

18.

Dominant TOM1 mutation associated with combined immunodeficiency and autoimmune disease.

Keskitalo S, Haapaniemi EM, Glumoff V, Liu X, Lehtinen V, Fogarty C, Rajala H, Chiang SC, Mustjoki S, Kovanen P, Lohi J, Bryceson YT, Seppänen M, Kere J, Heiskanen K, Varjosalo M.

NPJ Genom Med. 2019 Jun 27;4:14. doi: 10.1038/s41525-019-0088-5. eCollection 2019.

19.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.

20.

Therapy de-escalation before stopping in chronic myeloid leukaemia.

Mustjoki S.

Lancet Haematol. 2019 Jul;6(7):e345-e346. doi: 10.1016/S2352-3026(19)30093-6. Epub 2019 Jun 11. No abstract available.

PMID:
31201084

Supplemental Content

Loading ...
Support Center